Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage. Here, we report the development of bone-homing alendronate (ALN)-anchored biodegradable polymeric micelles for the targeted treatment of metastatic cancer to bone. These micelles exhibited bone protective capacity including the recruitment, differentiation, and resorption activity of the osteoclasts. Encapsulation of docetaxel (DTX), the first-line chemotherapeutic for treatment of metastatic breast cancer, in ALN-modified micelles results in a sustained release, enhanced cytotoxicity, and improved pharmacokinetics. In the syngeneic animal model of late-stage disseminated breast cancer bone metastasis, the treatment with targeted DTX-loaded micelles attenuated the tumorigenesis and significantly improved animal lifespan compared to the conventional surfactant-based formulation (free DTX). These findings indicate potential applications of the osteotropic nanomedicines for bone metastasis treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Successful targeted delivery of these drug-loaded micelles to the tumors using tumor-specific ligands attached to the micelle outer PEG chains were also described [179–181].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [181]
Citations
Cites
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases
Hartsell, W. F., Scott, C. B., Bruner, D. W., Scarantino, C. W., Ivker, R. A., Roach, M., Suh, J. H., Demas, W. F., Movsas, B., Petersen, I. A., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji139 · Cited by 823
Steenland, E., Leer, J., van Houwelingen, H., Post, W. J., van den Hout, W. B., Kievit, J., de Haes, H., Martijn, H., Oei, B., Vonk, E., et al. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00110-3 · Cited by 677
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
Ferrari, M., Fornasiero, M. C., & Isetta, A. M. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90187-z · Cited by 565
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Fluorescence probes for critical micelle concentration determination
Goddard, E. D., Turro, N. J., Kuo, P. L., & Ananthapadmanabhan, K. P. (1985) · Langmuir · doi:10.1021/la00063a015 · Cited by 456
Molecular Biology of Bone Metastasis
Kingsley, L. A., Fournier, P. G. J., Chirgwin, J. M., & Guise, T. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0234 · Cited by 435
A novel orthotopic model of breast cancer metastasis to bone
Lelekakis, M., Moseley, J. M., Martin, T. J., Hards, D., Williams, E., Ho, P., Lowen, D., Javni, J., Miller, F. R., Slavin, J., et al. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006689719505 · Cited by 427
Radionuclide Bone Imaging: An Illustrative Review
Love, C., Din, A. S., Tomas, M. B., Kalapparambath, T. P., & Palestro, C. J. (2003) · RadioGraphics · doi:10.1148/rg.232025103 · Cited by 422
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 393
Self-citationBisphosphonates and other bone agents for breast cancer
O'Carrigan, B., Wong, M. H., Willson, M. L., Stockler, M. R., Pavlakis, N., & Goodwin, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub4 · Cited by 356
Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases
Nielsen, O. S., Bentzen, S. M., Sandberg, E., Gadeberg, C. C., & Timothy, A. R. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(98)00011-5 · Cited by 326
Gaze, M. N., Kelly, C. G., Kerr, G. R., Cull, A., Cowie, V. J., Gregor, A., Howard, G. C. W., & Rodger, A. (1997) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(97)00101-1 · Cited by 284
Breast cancer metastasis to the bone: mechanisms of bone loss
Chen, Y.-C., Sosnoski, D. M., & Mastro, A. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2781 · Cited by 282
The role of amino acids in hydroxyapatite mineralization
Tavafoghi, M., & Cerruti, M. (2016) · Journal of The Royal Society Interface · doi:10.1098/rsif.2016.0462 · Cited by 264
Yasugi, K., Nagasaki, Y., Kato, M., & Kataoka, K. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00028-0 · Cited by 249
Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity
Clézardin, P., Ebetino, F. H., & Fournier, P. G. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0264 · Cited by 232
Docetaxel: A Review of its Use in Metastatic Breast Cancer
Lyseng-Williamson, K. A., & Fenton, C. (2005) · Drugs · doi:10.2165/00003495-200565170-00007 · Cited by 225
Delineation of the Hydroxyapatite-nucleating Domains of Bone Sialoprotein
Tye, C. E., Rattray, K. R., Warner, K. J., Gordon, J. A. R., Sodek, J., Hunter, G. K., & Goldberg, H. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211915200 · Cited by 210
Bone-targeting macromolecular therapeutics
WANG, D., MILLER, S., KOPECKOVA, P., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.011 · Cited by 203
Foro Arnalot, P., Fontanals, A. V., Galcerán, J. C., Lynd, F., Latiesas, X. S., de Dios, N. R., Castillejo, A. R., Bassols, M. L., Galán, J. L., Conejo, I. M., et al. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.05.018 · Cited by 203
Safety of Polysorbate 80 in the Oncology Setting
Schwartzberg, L. S., & Navari, R. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0707-z · Cited by 195
Targeted delivery to bone and mineral deposits using bisphosphonate ligands
Cole, L. E., Vargo-Gogola, T., & Roeder, R. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.005 · Cited by 190
Thamake, S. I., Raut, S. L., Gryczynski, Z., Ranjan, A. P., & Vishwanatha, J. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.026 · Cited by 182
Johns, J. L., & Christopher, M. M. (2012) · Veterinary Pathology · doi:10.1177/0300985811432344 · Cited by 181
Onco-Nephrology: The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia
Rosner, M. H., & Dalkin, A. C. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02470312 · Cited by 178
Ramanlal Chaudhari, K., Kumar, A., Megraj Khandelwal, V. K., Ukawala, M., Manjappa, A. S., Mishra, A. K., Monkkonen, J., & Ramachandra Murthy, R. S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.020 · Cited by 172
The role of tumour-associated macrophages in bone metastasis
Sousa, S., & Määttä, J. (2016) · Journal of Bone Oncology · doi:10.1016/j.jbo.2016.03.004 · Cited by 158
Animal Models of Bone Metastasis
Simmons, J. K., Hildreth, B. E., Supsavhad, W., Elshafae, S. M., Hassan, B. B., Dirksen, W. P., Toribio, R. E., & Rosol, T. J. (2015) · Veterinary Pathology · doi:10.1177/0300985815586223 · Cited by 151
Dendritic Poly(ethylene glycol) Bearing Paclitaxel and Alendronate for Targeting Bone Neoplasms
Clementi, C., Miller, K., Mero, A., Satchi-Fainaro, R., & Pasut, G. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2001445 · Cited by 121
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Self-citationKuchuk, I., Hutton, B., Moretto, P., Ng, T. L., Addison, C., & Clemons, M. J. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.09.001 · Cited by 109
Poly(lactide)‐poly(ethylene glycol) micelles as a carrier for griseofulvin
Pierri, E., & Avgoustakis, K. (2005) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30490 · Cited by 103
Miller, K., Eldar‐Boock, A., Polyak, D., Segal, E., Benayoun, L., Shaked, Y., & Satchi‐Fainaro, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200083n · Cited by 100
Ye, W.-L., Zhao, Y.-P., Li, H.-Q., Na, R., Li, F., Mei, Q., Zhao, M., & Zhou, S.-Y. (2015) · Scientific Reports · doi:10.1038/srep14614 · Cited by 99
Miller, K., Clementi, C., Polyak, D., Eldar‐Boock, A., Benayoun, L., Barshack, I., Shaked, Y., Pasut, G., & Satchi‐Fainaro, R. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.052 · Cited by 88
Srinivasan, R., Tan, L. P., Wu, H., Yang, P., Kalesh, K., & Yao, S. Q. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b902338k · Cited by 86
Fang, J., & Xu, Q. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1247-x · Cited by 64
Alendronate reduces osteoclast precursors in osteoporosis
D’Amelio, P., Grimaldi, A., Cristofaro, M. A., Ravazzoli, M., Molinatti, P. A., Pescarmona, G., & Isaia, G. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1129-1 · Cited by 57
Wang, X., Yang, Y., Jia, H., Jia, W., Miller, S. C., Bowman, B. M., Feng, J. X., & Zhan, F. (2014) · Biomaterials Science · doi:10.1039/c4bm00020j · Cited by 46
Poly(γ-benzyl-l-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting
de Miguel, L., Noiray, M., Surpateanu, G. G., Iorga, B. I., & Ponchel, G. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.10.048 · Cited by 45
Cleeland, C., von Moos, R., Walker, M. S., Wang, Y., Gao, J., Chavez-MacGregor, M., Liede, A., Arellano, J., Balakumaran, A., & Qian, Y. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3154-x · Cited by 41
The role of macrophages in bone metastasis
Vasiliadou, I., & Holen, I. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.07.002 · Cited by 34
Frings, P. W. H., van Elssen, C. H. M. J., Wieten, L., Matos, C., Hupperets, P. S. G. J., Schouten, H. C., Bos, G. M. J., & van Gelder, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1355-z · Cited by 21
Cleavage of Disulfide-Linked Fetuin−Bisphosphonate Conjugates with Three Physiological Thiols
Zhang, S., Wright, J. E. I., Bansal, G., Cho, P., & Uludağ, H. (2005) · Biomacromolecules · doi:10.1021/bm050273s · Cited by 18
Fernandes, C., Monteiro, S. B., Belchior, A., Marques, F., Gano, L., Correia, J. D. G., & Santos, I. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.11.004 · Cited by 15
Logie, J., McLaughlin, C. K., Tam, R. Y., & Shoichet, M. S. (2015) · Chemical Communications · doi:10.1039/c5cc04282h · Cited by 10
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Ashrafizadeh, M., Zarrabi, A., Bigham, A., Taheriazam, A., Saghari, Y., Mirzaei, S., Hashemi, M., Hushmandi, K., Karimi‐Maleh, H., Nazarzadeh Zare, E., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.21971 · Cited by 207
“Polymeric micelles are of particular interest because of their easy‐to‐tailor structure.(179,180) Paclitaxel drug molecules were entrapped in an acid‐labile, bone‐modified, PEGylated micellar system.”
BackgroundThe past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 159
The advances in nanomedicine for bone and cartilage repair
Qiao, K., Xu, L., Tang, J., Wang, Q., Lim, K. S., Hooper, G. J., Woodfield, T. B. F., Liu, G., Tian, K., Zhang, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01342-8 · Cited by 138
“Therefore, this system had the potential to treat metastatic bone tumours [80].”
BackgroundJunnuthula, V., Kolimi, P., Nyavanandi, D., Sampathi, S., Vora, L. K., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091860 · Cited by 126
“5 PEG-PGlu-PPhA DOX, ALN Late-stage breast cancer bone metastasis [71]”
Background
Metadata
- Authors
- Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K.
- Affiliations
- Nebraska Medical Center (US)
- Corresponding author
- Bronich, Tatiana K.
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-05-31
- Volume
- 16
- Issue
- 7
- Pages
- 2872-2883
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- PMC
- PMC6632075
- OpenAlex
- W2947085578
- Cited by
- 34
- References
- 48
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 3
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U01 CA198910)
- China Scholarship Council ([2003]3009)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- breast cancer bone metastasis, alendronate, polymeric micelles, docetaxel, osteoclastogenesis, osteoclast resorption, biodegradable micelles, targeted drug delivery, sustained drug release, pharmacokinetics
- MeSH terms
- RAW 264.7 Cells, Docetaxel, Animals, Antineoplastic Agents, Bone Neoplasms, Breast Neoplasms, Female, Mice, Inbred BALB C, Micelles, Polymers, Transplantation, Homologous, Treatment Outcome, Alendronate, Cell Line, Tumor, Bone Density Conservation Agents, Mice, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.